Nexus Pharmaceuticals, Inc.

27 articles about Nexus Pharmaceuticals, Inc.

• Nexus Pharmaceuticals, Inc. Receives Successful FDA Inspection of Pharmaceutical Manufacturing Facility in Pleasant Prairie, Wisconsin

  5/5/2023

  Nexus Pharmaceuticals, Inc. announced that its pharmaceutical manufacturing facility in Pleasant Prairie, Wisconsin, was successfully inspected by the Food and Drug Administration, which will allow Nexus to begin commercial operations.

• Nexus Pharmaceuticals, Inc. Receives FDA Approval for EMERPHED® (ephedrine sulfate injection) Pre-Filled Syringe

  3/1/2023

  Nexus Pharmaceuticals, Inc. announced that it has received US Food and Drug Administration (FDA) approval for EMERPHED® (ephedrine sulfate injection) in 25mg/5mL and 50mg/10mL single-dose pre-filled syringes.

• Nexus Pharmaceuticals Announces Launch of Sterile Vial Product Line

  2/22/2023

  Nexus Pharmaceuticals, Inc. announced the launch of its new product line – Sterile Vials from Nexus Pharmaceuticals.

• Nexus Pharmaceuticals Inc. Receives FDA Approval for Tirofiban Hydrochloride Injection

  2/9/2023

  Nexus Pharmaceuticals Inc. announced that it has received US Food and Drug Administration (FDA) approval for Tirofiban Hydrochloride Injection in 5mg/100mL single-dose IV-bags.

• Nexus Pharmaceuticals Announces Usman Ahmed as President and Chief Executive Officer

  10/3/2022

  Nexus Pharmaceuticals, Inc., a U.S.-based healthcare company and certified diverse supplier, has announced that Usman Ahmed has been named as President and Chief Executive Officer.

• Nexus Pharmaceuticals Announces Launch of Erythromycin Lactobionate for Injection, USP

  4/21/2022

  Nexus Pharmaceuticals announced the launch of Erythromycin Lactobionate for Injection, USP in 500mg/vial in single-dose vials. It is an AP-rated generic to ERYTHROCIN™.

• Nexus Pharmaceuticals Inc. Receives FDA Approval of Erythromycin Lactobionate for Injection, USP

  2/17/2022

  Nexus Pharmaceuticals Inc. announced that it has received US Food and Drug Administration (FDA) approval for Erythromycin Lactobionate for Injection, USP in 500mg/vial in single-dose vials. It is an AP-rated generic to ERYTHROCIN™.

• Nexus Pharmaceuticals Receives Patent for EMERPHED® Ready-To-Use Ephedrine Sulfate Injection

  8/17/2021

  Nexus Pharmaceuticals Receives Patent for EMERPHED ® Ready-To-Use Ephedrine Sulfate Injection

• Nexus Pharmaceuticals Announces Launch of Potassium Chloride in Water for Injection

  7/26/2021

  Nexus Pharmaceuticals announced the launch of Potassium Chloride in Water for Injection in 10mEq/100mL, 10mEq/50mL, and 20mEq/50mL Single-Dose IV bags.

• Nexus Pharmaceuticals Celebrates Grand Opening of New, State-of-the-Art Manufacturing Facility

  7/19/2021

  On Friday, July 16, 2021, Nexus Pharmaceuticals, Inc., a U.S.-based healthcare company and domestic pharmaceutical manufacturer, celebrated the opening of Project Tomorrow—the company’s new, state-of-the-art manufacturing facility in Pleasant Prairie, Wisconsin.

• Nexus Pharmaceuticals Announces Launch of Succinylcholine Chloride Injection, USP

  4/26/2021

  Nexus Pharmaceuticals announced the launch of Succinylcholine Chloride Injection, USP in 200mg/10mL Multiple-Dose Vials. It is an AP-rated generic to QUELICIN™¥.

• Nexus Pharmaceuticals Makes Key Investment to Help COVID-19 Vaccine Effort

  4/14/2021

  Nexus Pharmaceuticals Inc., a US-based healthcare company and domestic manufacturer, today announced that they transported via a special air freight charter through DB Schenker 82 tons of vaccine filling equipment, including a vaccine filling machine and isolator from Bausch + Stroebel and Franz Ziel.

• Nexus Pharmaceuticals Announces Verbal to Occupy Authorization

  3/26/2021

  Nexus Pharmaceuticals, Inc. is pleased to announce that it has received authorization to occupy its new pharmaceutical manufacturing facility from the Village of Pleasant Prairie, Wisconsin.

• Nexus Pharmaceuticals Receives FDA Approval for Potassium Chloride in Water for Injection

  3/25/2021

  Nexus Pharmaceuticals announced today that it has received U.S. Food and Drug Administration (FDA) approval for Potassium Chloride in Water for Injection in 10mEq/100mL, 10mEq/50mL, 20mEq/100mL, 40mEq/100mL and 20mEq/50mL Single-Dose IV bags.

• Nexus Pharmaceuticals Stands Ready to Support Efforts to Increase Vaccine Manufacturing

  2/11/2021

  Nexus Pharmaceuticals supports the Biden-Harris administration’s decision to invoke the Defense Production Act (DPA) in order to boost supplies needed for COVID-19 vaccine production and for at-home virus test kits.

• Nexus Pharmaceuticals Announces Diversity Certification

  12/3/2020

  Nexus Pharmaceuticals is pleased to announce their continuous certification as a Minority Business Enterprise (MBE) and a Women’s Business Enterprise (WBE).

• Nexus Pharmaceuticals Receives FDA Approval for Succinylcholine Chloride Injection, USP

  10/29/2020

  Nexus Pharmaceuticals announced it has received U.S. Food and Drug Administration (FDA) approval for Succinylcholine Chloride Injection, USP in 200mg/10mL Multiple-Dose Vials. It is an AP-rated generic to QUELICIN™ ¥ . “Nexus Pharmaceuticals is very pleased to announce the approval of Succinylcholine Chloride. This critical need drug has seen an increased demand due to the COVID-19 pandemic and Nexus will be read

• Nexus Pharmaceuticals, Inc. Announces Launch of Emerphed™ (ephedrine sulfate) RTU Injection, the First and Only FDA-approved, Ready-to-Use Ephedrine Injection (50 mg/10 mL vial)

  6/26/2020

  Nexus Pharmaceuticals announced today that it has launched its patent-pending New Drug Application (NDA) Emerphed, the first and only premixed ephedrine in a ready-to-use 50 mg/10 mL vial. With no need for compounding, diluting, or mixing, Emerphed saves valuable staff time while also reducing the potential for preparation error and waste. This press release features multimedia. View the full release here: https:/

• Nexus Pharmaceuticals, Inc. Announces Approval of Emerphed™ (ephedrine sulfate) Injection, the First and Only FDA-approved, Ready-to-Use Ephedrine Injection (50 mg/10 mL vial)

  4/21/2020

  Nexus Pharmaceuticals announced today it has received U.S. Food and Drug Administration (FDA) approval for its patent-pending New Drug Application (NDA) Emerphed, the first and only premixed ephedrine in a ready-to-use 50 mg/10 mL vial.

• Nexus Pharmaceuticals to Build Industry-Leading Sterile Injectable Manufacturing Facility in Pleasant Prairie, Wisconsin

  7/10/2019

  Nexus Pharmaceuticals will invest $250 million to build U.S. based pharmaceutical facility bringing hundreds of new high-tech manufacturing jobs to Wisconsin